Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-β concentrations and cognition outcomes in Alzheimer’s disease patients: a multicenter, randomized, controlled clinical trial
Manuscript Number:
16-0565R1
Author(s):
Montserrat Alegret, Fernando Anaya, Mercè Boada, Mar Buendía, Isidre Ferrer, Joan Ramon Grifols, Isabel Hernández, Asunción Lafuente, Oscar Lopez, Joan Muñoz, Laura Núñez, Thomas O. Obisesan, Javier Olazarán, Pilar Ortiz, Antonio Páez, Joshua R. Shua-Haim, Mireia Torres, Lluís Tárraga
Disclosures
Montserrat Alegret
Nothing to Disclose
Fernando Anaya
Nothing to Disclose
Mercè Boada
Consulting Fees:
Dr. M. Boada has consulted for Araclon, Avid, Bayer, Elan, Grifols, Janssen/Pfizer, Lilly, Neuroptix, Nutricia, Roche, Sanofi and Servier.
Lecture Fees:
She received fees for lectures and funds for research from Araclon, Esteve, Grifols, Janssen, Novartis, Nutricia, Piramal, Pfizer-Wyett, Roche and Servier.
Grants
Agency:
EFSD - European Foundation for the Study of Diabetes. EFSD/Lilly Mental Health and Diabetes Programme.